D-glucaro-1,5-lactone | 10366-77-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: D-glucaro-1,5-lactone
• 英文别名: D-glucono-1,5-lactone；(2S,3S,4S,5R)-3,4,5-trihydroxy-6-oxooxane-2-carboxylic acid
• CAS: 10366-77-5；10366-81-1
• 化学式: C₆H₈O₇
• 分子量: 192.125
• InChiKey: YLKFQNUGXOLRNI-QDQPNEQZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.8
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  124
• 氢给体数：
  4
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  D-吡喃葡萄糖醛酸 在 platinum on activated charcoal 氢氧化钾 作用下， 以 水 为溶剂， 25.0 ℃ 、101.32 kPa 条件下， 反应 5.0h， 生成 D-glucaro-1,5-lactone
  参考文献：
  名称：

  碱性溶液中还原糖的催化脱氢

  摘要：

  摘要碱性介质中的醛类在铂或铑的催化作用下被高选择性地转化为醛糖酸，并伴随着氢气的逸出。已经针对25种不同的单糖和二糖研究了脱氢反应，该反应通常可用于还原糖。研究了几个反应变量的影响，得出了一个吸附模型，在该模型中，带负电荷的O-1和H-1与催化剂表面的紧密接触均被视为推动氢化物从C-转移的动力。将1的糖加入催化剂中。

  DOI：

  10.1016/s0008-6215(00)86025-5

文献信息

• Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse
  申请人：Fred Hutchinson Cancer Research Center

  公开号：US10702551B2

  公开（公告）日：2020-07-07

  The present disclosure provides compositions and methods for the delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse. The compositions comprise (i) a structure comprising an injectable polymer or scaffold comprising pores; (ii) lymphocytes disposed within the structure, (iii) at least one lymphocyte-adhesion moiety associated with the structure; and (iv) at least one lymphocyte-activating moiety associated with the structure, and optionally an immune stimulant.

  本公开提供了用于递送免疫细胞以治疗无法切除或无法切除的肿瘤细胞和肿瘤复发的组合物和方法。这些组合物包括：(i) 由包含孔隙的可注射聚合物或支架组成的结构；(ii) 布置在该结构内的淋巴细胞；(iii) 至少一种与该结构相关的淋巴细胞粘附分子；(iv) 至少一种与该结构相关的淋巴细胞激活分子，以及可选的免疫刺激剂。
• COMPOSITIONS AND METHODS FOR DELIVERY OF IMMUNE CELLS TO TREAT UN-RESECTABLE OR NON-RESECTED TUMOR CELLS AND TUMOR RELAPSE
  申请人：Fred Hutchinson Cancer Research Center

  公开号：EP2943565B1

  公开（公告）日：2018-03-28
• SCAFFOLDS TO TREAT SOLID TUMOR CELLS AND ESCAPE VARIANTS
  申请人：Fred Hutchinson Cancer Research Center

  公开号：EP3558327A1

  公开（公告）日：2019-10-30
• Porous Polymer Scaffolds for Neural Tissue Engineering and Methods of Producing the Same
  申请人：WEGST Ulrike G.K.

  公开号：US20120149111A1

  公开（公告）日：2012-06-14

  The present invention relates to scaffolds that can physically guide cells, e.g. neurons, while best matching the material properties of native tissue. The present invention also relates to methods of generating such scaffolds, and for the use of such scaffolds, e.g. in spinal cord and peripheral nerve injury repair. The methods of the present invention include a uniquely controlled freeze casting process to generate highly porous, linearly oriented scaffolds. The scaffolds of the present invention not only comprise a highly aligned porosity, but also contain secondary guidance structures in the form of ridges running parallel to the pores to create a series of microstructured and highly aligned channels. This hierarchy of structural guidance aligns and guides neurite outgrowth down the channels created by the ridges, and keep neurites from branching perpendicular to the inter-ridge grooves.
• COMPOSITIONS AND METHODS FOR PRODUCING CHEMICALS AND DERIVATIVES THEREOF
  申请人：Synthetic Genomics, Inc.

  公开号：US20140206047A1

  公开（公告）日：2014-07-24

  The present invention provides methods for producing a product of one or more enzymatic pathways. The pathways used in the methods of the invention involve one or more conversion steps such as, for example, an enzymatic conversion of guluronic acid into D-glucarate (Step 7); an enzymatic conversion of 5-ketogluconate (5-KGA) into L-Iduronic acid (Step 15); an enzymatic conversion of L-Iduronic acid into Idaric acid Step 7b); and an enzymatic conversion of 5-ketocluconate into 4,6-dihydroxy 2,5-diketo hexanoate (2,5-DDH) (Step 16). In some embodiments the methods of the invention produce 2,5-furandicarboxylic acid (FDCA) as a product. The methods include both enzymatic and chemical conversions as steps. Various pathways are also provided for converting glucose into 5-dehdyro-4-deoxy-glucarate (DDG), and for converting glucose into 2,5-furandicarboxylic acid (FDCA). The methods also involve the use of engineered enzymes that perform reactions with high specificity and efficiency. Additional products that can be produce include metabolic products such as, but not limited to, guluronic acid, L-iduronic acid, idaric acid, glucaric acid. Any of the products can be produced using glucose as a substrate or using any intermediate in any of the methods or pathways of the invention.